Copyright Reports & Markets. All rights reserved.

Global Immune Thrombocytopenic Purpura Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Immune Thrombocytopenic Purpura Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Product
      • 1.4.2 Eltrombopag Olamine
      • 1.4.3 Fostamatinib Disodium
      • 1.4.4 GL-2045
      • 1.4.5 Avatrombopag
      • 1.4.6 BI-655064
      • 1.4.7 Others
    • 1.5 Market by End User
      • 1.5.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size
      • 2.1.1 Global Immune Thrombocytopenic Purpura Therapeutics Revenue 2014-2025
      • 2.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Sales 2014-2025
    • 2.2 Immune Thrombocytopenic Purpura Therapeutics Growth Rate by Regions
      • 2.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales by Regions
      • 2.2.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Immune Thrombocytopenic Purpura Therapeutics Sales by Manufacturers
      • 3.1.1 Immune Thrombocytopenic Purpura Therapeutics Sales by Manufacturers
      • 3.1.2 Immune Thrombocytopenic Purpura Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Immune Thrombocytopenic Purpura Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Immune Thrombocytopenic Purpura Therapeutics Revenue by Manufacturers
      • 3.2.1 Immune Thrombocytopenic Purpura Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Immune Thrombocytopenic Purpura Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Immune Thrombocytopenic Purpura Therapeutics Price by Manufacturers
    • 3.4 Immune Thrombocytopenic Purpura Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Immune Thrombocytopenic Purpura Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Immune Thrombocytopenic Purpura Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Immune Thrombocytopenic Purpura Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales by Product
    • 4.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Product
    • 4.3 Immune Thrombocytopenic Purpura Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Immune Thrombocytopenic Purpura Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Immune Thrombocytopenic Purpura Therapeutics by Countries
      • 6.1.1 North America Immune Thrombocytopenic Purpura Therapeutics Sales by Countries
      • 6.1.2 North America Immune Thrombocytopenic Purpura Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Immune Thrombocytopenic Purpura Therapeutics by Product
    • 6.3 North America Immune Thrombocytopenic Purpura Therapeutics by End User

    7 Europe

    • 7.1 Europe Immune Thrombocytopenic Purpura Therapeutics by Countries
      • 7.1.1 Europe Immune Thrombocytopenic Purpura Therapeutics Sales by Countries
      • 7.1.2 Europe Immune Thrombocytopenic Purpura Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Immune Thrombocytopenic Purpura Therapeutics by Product
    • 7.3 Europe Immune Thrombocytopenic Purpura Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics by Countries
      • 8.1.1 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics by Product
    • 8.3 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Immune Thrombocytopenic Purpura Therapeutics by Countries
      • 9.1.1 Central & South America Immune Thrombocytopenic Purpura Therapeutics Sales by Countries
      • 9.1.2 Central & South America Immune Thrombocytopenic Purpura Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Immune Thrombocytopenic Purpura Therapeutics by Product
    • 9.3 Central & South America Immune Thrombocytopenic Purpura Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics by Countries
      • 10.1.1 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics by Product
    • 10.3 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics by End User

    11 Company Profiles

    • 11.1 Amgen Inc.
      • 11.1.1 Amgen Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.1.5 Amgen Inc. Recent Development
    • 11.2 Baxalta Incorporated
      • 11.2.1 Baxalta Incorporated Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.2.5 Baxalta Incorporated Recent Development
    • 11.3 Boehringer Ingelheim GmbH
      • 11.3.1 Boehringer Ingelheim GmbH Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.3.5 Boehringer Ingelheim GmbH Recent Development
    • 11.4 Bristol-Myers Squibb Company
      • 11.4.1 Bristol-Myers Squibb Company Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.4.5 Bristol-Myers Squibb Company Recent Development
    • 11.5 Eisai
      • 11.5.1 Eisai Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Eisai Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Eisai Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.5.5 Eisai Recent Development
    • 11.6 Hansa Medical AB
      • 11.6.1 Hansa Medical AB Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.6.5 Hansa Medical AB Recent Development
    • 11.7 Immunomedics, Inc.
      • 11.7.1 Immunomedics, Inc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.7.5 Immunomedics, Inc. Recent Development
    • 11.8 Intas Pharmaceuticals Ltd.
      • 11.8.1 Intas Pharmaceuticals Ltd. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.8.5 Intas Pharmaceuticals Ltd. Recent Development
    • 11.9 Jiangsu Hengrui Medicine Co., Ltd.
      • 11.9.1 Jiangsu Hengrui Medicine Co., Ltd. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.9.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
    • 11.10 Merck & Co., Inc.
      • 11.10.1 Merck & Co., Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Products Offered
      • 11.10.5 Merck & Co., Inc. Recent Development
    • 11.11 Momenta Pharmaceuticals, Inc.
    • 11.12 Novartis AG
    • 11.13 Pfizer Inc.

    12 Future Forecast

    • 12.1 Immune Thrombocytopenic Purpura Therapeutics Market Forecast by Regions
      • 12.1.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Immune Thrombocytopenic Purpura Therapeutics Market Forecast by Product
      • 12.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Immune Thrombocytopenic Purpura Therapeutics Market Forecast by End User
    • 12.4 North America Immune Thrombocytopenic Purpura Therapeutics Forecast
    • 12.5 Europe Immune Thrombocytopenic Purpura Therapeutics Forecast
    • 12.6 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Forecast
    • 12.7 Central & South America Immune Thrombocytopenic Purpura Therapeutics Forecast
    • 12.8 Middle East and Africa Immune Thrombocytopenic Purpura Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Immune Thrombocytopenic Purpura Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Immune Thrombocytopenic Purpura Therapeutics market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Immune Thrombocytopenic Purpura Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Immune Thrombocytopenic Purpura Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Immune Thrombocytopenic Purpura Therapeutics in these regions.
      This research report categorizes the global Immune Thrombocytopenic Purpura Therapeutics market by top players/brands, region, type and end user. This report also studies the global Immune Thrombocytopenic Purpura Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Amgen Inc.
      Baxalta Incorporated
      Boehringer Ingelheim GmbH
      Bristol-Myers Squibb Company
      Eisai
      Hansa Medical AB
      Immunomedics, Inc.
      Intas Pharmaceuticals Ltd.
      Jiangsu Hengrui Medicine Co., Ltd.
      Merck & Co., Inc.
      Momenta Pharmaceuticals, Inc.
      Novartis AG
      Pfizer Inc.

      Market size by Product
      Eltrombopag Olamine
      Fostamatinib Disodium
      GL-2045
      Avatrombopag
      BI-655064
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Immune Thrombocytopenic Purpura Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Immune Thrombocytopenic Purpura Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Immune Thrombocytopenic Purpura Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Immune Thrombocytopenic Purpura Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Immune Thrombocytopenic Purpura Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Immune Thrombocytopenic Purpura Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now